Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-03-21

Clinical Trial Update: Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating incobotulinumtoxinA (Xeomin) for relief of restless legs syndrome symptoms has completed, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • XEOMIN (INCOBOTULINUMTOXINA)

Snippet

Sponsor: Yale University | Conditions: Restless Leg Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2016-03-21